Clinical Trials Directory

Trials / Completed

CompletedNCT03708887

The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients

Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
415 (actual)
Sponsor
Zhejiang University · Academic / Other
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

A double-blind and placebo-controlled study is conducted in the current human study. The purpose of this study is to investigate the effects of n-3 PUFA intervention on glucose and lipid homeostasis in Chinese diabetic/obese patients.

Detailed description

Approximately 450 diabetic and 450 obese patients will be enrolled from Lanxi in China. They will be randomly assigned into one of the following three groups: Omega-3 fatty acids capsules (1.5 g/d); or omega-3 fatty acids capsules (3 g/d); or placebo capsules. Blood, feces and urine samples will be collected before and after treatment. Glucose and lipid parameters will be measured. Diabetes comorbidities and complications will also be assessed. This study will also explore the new mechanisms of n-3 PUFAs on improving glucose and lipid homeostasis and other outcomes based on multi-omics and establish a model for precision intervention.

Conditions

Interventions

TypeNameDescription
DRUGLow dose omega-3 fatty acid supplementationOmega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
DRUGHigh dose omega-3 fatty acid supplementationOmega-3 fatty acids capsules, 3 g/d by mouth for 1 year
DRUGControl drugMatching placebo capsules,3 g/d by mouth for 1 year

Timeline

Start date
2020-10-10
Primary completion
2022-01-02
Completion
2022-02-28
First posted
2018-10-17
Last updated
2024-07-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03708887. Inclusion in this directory is not an endorsement.